VP of Business Development at Poolbeg Pharma, David English, gives an overview of his experience and why he decided to join the Poolbeg Pharma team.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
Poolbeg Pharma has been granted a patent in the United States for the treatment of hypercytokinaemia using its new influenza drug POLB 001. The US patent covers the use of POLB 001 and related p38 MAP kinase inhibitors
Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections. POLB 001 showed success in reducing multiple markers
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia
Poolbeg Pharma – a company focused on developing infectious disease therapies – has announced data from its bacterial lipopolysaccharide (LPS) human challenge trial for POLB 001. The treatment is a viral strain agnostic, small molecule immunomodulator which is
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF’), a leading infectious disease focused biopharmaceutical company, has announced the data readout from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine, to how Brexit has changed the world’s relationship
Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK. Chances are RSV, or respiratory syncytial virus, which has symptoms similar to
Poolbeg Pharma (LON:POLB / OTCQB:POLBF) Investment Case with CEO Jeremy Skillington. Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a unique capital light model. The company is focus on targeting the significant global medical need to treat
While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
A Donegal man hopes to raise one billion dollars when his latest venture launches on New York’s Nasdaq. Poolbeg Pharma is planning to list on the stock exchange as chairman Cathal Friel (58), from Creeslough, eyes another $1bn
CAR-T therapies capitalize on the activities of T cells, the immune system’s natural hunters that prowl through the body looking for things that don’t belong. Foreign cells, or those infected with a virus, express unusual proteins that serve
While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers
Poolbeg Pharma, a biopharmaceutical company that specialises in infectious diseases, has filed a patent for one of its treatments to be used in cancer treatments. The treatment, called POLB 001, was developed to address severe influenza, but it
Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced the strategic expansion of POLB 001 into oncology. While investigating the role of cytokine release syndrome in severe influenza, Poolbeg discovered data specific to the overt immune
In a proof-of-concept clinical trial, Poolbeg Pharma will look into the potential of microencapsulation and nanoencapsulation oral delivery technologies. Poolbeg Pharma has acquired a licence from a sister company of Cork start-up AnaBio Technologies for an innovative treatment
© 2022 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.